Skip to main content
| News

Alloy acquires deepCDR and will expand Basel site

10.12.2021

Alloy Therapeutics, a biotechnology firm from Boston in the USA, has acquired the Basel-based startup deepCDR Biologics. Alloy labs and deepCDR facilities in Basel are to be expanded into a permanent research center.

Alloy Therapeutics has acquired the startup deepCDR Biologics and opted for Basel as the location for a permanent research facility. According to a press release issued by the biotechnology firm from the US city of Boston, Alloy is acquiring the Basel-based startup with the aim of using its new antibody discovery and development method. Alloy already operates labs in Basel, but following the takeover of deepCDR will seek to transfer its facilities to a permanent Alloy research center.

Additional computer scientists and developers are to be hired at the Basel site as the Alloy network grows. Basel is set to become the location for bioinformatics and machine learning in the discovery of antibodies. The deepCDR team and technology will strengthen Alloy’s antibody discovery platform and system services from more than 100 global partners, the press release states.

DeepCDR Biologics is a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH). Only last year, it successfully patented its new discovery and development method for antibodies. This should accelerate the development of next-generation antibody drugs. The new method makes use of the deep learning capabilities and is also faster and significantly more cost-effective than previous methods.

Errik Anderson, CEO and founder of Alloy Therapeutics, expects that his firm’s network partners will use the deepCDR method to open up research opportunities “that otherwise would have been cost prohibitive or inaccessible”. These types of technological improvements will serve to enhance the output of Alloy in terms of drug research activities, Anderson adds.

“The data sets and infrastructure within Alloy unlock powerful new opportunities for the deepCDR technology and team that will in turn enable us to help drug discovery teams more effectively and efficiently find the best antibody candidates”, explains Sai Reddy, founder of deepCDR, in discussing the cooperation in the press release.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Sustainability

Evolva launches new line for manufacturers of personal care products

Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Record figure for startups in the Basel Area

Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...

Read More
Noema Pharma raises 103 million Swiss francs from investors
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Noema Pharma raises 103 million Swiss francs from investors

Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Why CDMO companies choose the Basel Area as their location

Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel still the most attractive small city for business in Europe

As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Ariceum Therapeutics establishes subsidiary in Basel

The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...

Read More
1 2 3 61

Do you have a question? We'd like to hear from you.